Longevitix announces Eric Verdin collaboration for AI-supported preventive care
Published in Artificial Intelligence, Personalized medicine, Tech News.
Published October 17, 2026.
Longevitix announced on October 13 that it will collaborate with Eric Verdin, president and CEO of the Buck Institute for Research on Aging, on the scientific direction of its preventive and longevity medicine platform.
The company says Verdin will help guide its approach to personalized, data-driven care. The announcement describes a collaboration with Verdin; it does not report a clinical trial or establish that the platform extends lifespan.
According to Longevitix, its software combines medical records, laboratory results, imaging, wearable measurements and lifestyle information to support clinicians. Proposed features include care-plan suggestions linked to scientific evidence, configurable workflows and tools for following patients between appointments. Physicians remain responsible for care decisions.
For longevity medicine, the practical question is whether such systems can turn diverse patient data into useful, reliable recommendations. That requires evidence beyond a collaboration announcement: independent validation, assessment of errors and prospective measurement of patient outcomes.
The release presents the company’s development goals and product description. It provides no comparative clinical results demonstrating better health outcomes or longer healthy life from using the platform.